ЖурналыПодпискаАрхивКнигиПроектыО насРекламаДоставка/ОплатаКонтакты
+7 (495) 482-43-29
  • Главная
  • / Журналы
  • / Вернуться в журнал
  • / Содержание номера
  • / Статья
Синдром дефицита внимания и гиперактивности: фармакотерапия в особых ситуациях

Синдром дефицита внимания и гиперактивности: фармакотерапия в особых ситуациях

Авторы:
Заваденко Н.Н.

Журнал: Журнал неврологии и психиатрии им. С.С. Корсакова. 2025;125(10):59-65.

DOI: 10.17116/jnevro202512510159

Прочитано: 1976 раз

Резюме

Синдром дефицита внимания и гиперактивности (СДВГ) является распространенной формой расстройств нервно-психического развития. Помимо основных симптомов, у пациентов с СДВГ часто наблюдаются проявления нейрокогнитивной дисфункции (дефицит управляющих функций, речи, низкий темп когнитивной деятельности), а примерно у 2/3 детей с установленным СДВГ диагностируется еще одно коморбидное расстройство. При выборе фармакотерапии предпочтительны препараты с положительным влиянием на симптомы как СДВГ, так и коморбидных расстройств. К их числу относится атомоксетина гидрохлорид. Рассматриваются возможности применения атомоксетина при коморбидности СДВГ с деструктивным поведением, тревожными расстройствами, нарушениями сна, ночным энурезом, тиками, заиканием, дислексией, а также влияние атомоксетина на показатели низкого когнитивного темпа, управляющих функций. Обсуждаются пути оптимального дозирования и минимизации нежелательных явлений при лечении атомоксетином.

Ключевые слова

  • синдром дефицита внимания и гиперактивности
  • атомоксетин
  • коморбидность
  • деструктивное поведение
  • тревожные расстройства
  • нарушения сна
  • дислексия
  • низкий когнитивный темп
  • управляющие функции

Дата поступления: 21.08.2025

Дата принятия в печать: 15.09.2025

Дата публикации: 19.11.2025

Литература / References
  1. Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789-818. https://doi.org/10.1016/j.neubiorev.2021.01.022
  2. Wolraich ML, Hagan JF Jr, Allan C, et al; Subcommittee on children and adolescents with Attention-Deficit/Hyperactive Disorder. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528. https://doi.org/10.1542/peds.2019-2528
  3. Faraone SV, Bellgrove MA, Brikell I, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2024;10(1):11. https://doi.org/10.1038/s41572-024-00495-0
  4. Song P, Zha M, Yang Q, et al. The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. J Glob Health. 2021;11:4009. https://doi.org/10.7189/jogh.11.04009
  5. Hutchison SL, Ghuman JK, Ghuman HS, et al. Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. Ther Adv Psychopharmacol. 2016;6(5):317-334. https://doi.org/10.1177/2045125316647686
  6. Drechsler R, Brem S, Brandeis D, et al. ADHD: Current Concepts and Treatments in Children and Adolescents. Neuropediatrics. 2020;51(5):315-335. https://doi.org/10.1055/s-0040-1701658
  7. Хачатрян Л.Г., Халецкая О.В., Скипетрова Л.А. и др. Проблема коморбидных расстройств при синдроме дефицита внимания с гиперактивностью у детей и подростков и их коррекция: клинические наблюдения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(9-2):51-57. https://doi.org/10.17116/jnevro202312309251
  8. Brown KA, Samuel S, Patel DR. Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: A review for practitioners. Transl Pediatr. 2018;7(1):36-47. https://doi.org/10.21037/tp.2017.08.02
  9. Caye A, Swanson JM, Coghill D, Rohde LA. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry. 2019;24(3):390-408. https://doi.org/10.1038/s41380-018-0116-3
  10. Da Silva BS, Grevet EH, Silva LCF, et al. An overview on neurobiology and therapeutics of attention-deficit/hyperactivity disorder. Discov Ment Health. 2023;3(1):2. https://doi.org/10.1007/s44192-022-00030-1
  11. Childress AC. A critical appraisal of atomoxetine in the management of ADHD. Ther Clin Risk Manag. 2016;12:27-39. https://doi.org/10.2147/TCRM.S59270
  12. Ковалев Г.И., Сухорукова Н.А., Васильева Е.В. и др. Влияние пантогама и атомоксетина на устойчивость внимания и распределение дофаминовых D2 и ГАМКВ-рецепторов у мышей с моделью дефицита внимания. Биомедицинская химия. 2021;67(5):402-410. https://doi.org/10.18097/PBMC20216705402
  13. Callahan PM, Plagenhoef MR, Blake DT, Terry AV Jr. Atomoxetine improves memory and other components of executive function in young-adult rats and aged rhesus monkeys. Neuropharmacology. 2019;155:65-75. https://doi.org/10.1016/j.neuropharm.2019.05.016
  14. Fu D, Wu D-D, Guo H-L, et al. The Mechanism, Clinical Efficacy, Safety, and Dosage Regimen of Atomoxetine for ADHD Therapy in Children: A Narrative Review. Front Psychiatry. 2022;12:780-921. https://doi.org/10.3389/fpsyt.2021.780921
  15. Zhang Y, Yin L, You C, et al. Efficacy and Safety of Methylphenidate and Atomoxetine in Medication-Naive Children with Attention-Deficit Hyperactivity Disorder in a Real-World Setting. Drugs R D. 2024;24(1):29-39. https://doi.org/10.1007/s40268-023-00445-3
  16. Schwartz S, Correll C. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53(2):174-187. https://doi.org/10.1016/j.jaac.2013.11.005
  17. Dell’Agnello G, Zuddas A, Masi G, et al. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs. 2009;23(9):739-753. https://doi.org/10.2165/11314350-000000000-00000
  18. Dittmann RW, Schacht A, Helsberg K, et al. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. J Child Adolesc Psychopharmacol. 2011;21(2):97-110. https://doi.org/10.1089/cap.2009.0111
  19. Newcorn JH, Spencer TJ, Biederman J, et al. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(3):240-248. https://doi.org/10.1097/00004583-200503000-00008
  20. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1119-1127. https://doi.org/10.1097/chi.0b013e3180ca8385
  21. Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009;26(3):212-221. https://doi.org/10.1002/da.20549
  22. Reimherr FW, Marchant BK, Strong RE, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry. 2005;58(2):125-131. https://doi.org/10.1016/j.biopsych.2005.04.040
  23. Khoodoruth MAS, Ouanes S, Khan YS. A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder. Res Dev Disabil. 2022;128:104275. https://doi.org/10.1016/j.ridd.2022.104275
  24. Karbasi A, Aghili S. Atomoxetine Versus Combination of Methylphenidate Plus Fluoxetine for Management of Anxiety Disorders in ADHD Children: A Randomized Clinical Trial. Iran J Psychiatry Behav Sci. 2023;17(2):e135121. https://doi.org/10.5812/ijpbs-135121
  25. Rocha NS, Correa RDESA, Dias ACM, Bueno CDF. Association between sleep pattern and pharmacological treatment in children with attention deficit disorder with hyperactivity: a systematic review. Rev Paul Pediatr. 2023;41:e2022065. https://doi.org/10.1590/1984-0462/2023/41/2022065
  26. Пальчик А.Б., Калашникова Т.П., Понятишин А.Е., Анисимов Г.В. Сон и его расстройства у детей. М.: МЕДпресс-информ. 2022;64.
  27. Hollway JA, Mendoza-Burcham M, Andridge R, et al. Atomoxetine, Parent Training, and Their Effects on Sleep in Youth with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2018;28(2):130-135. https://doi.org/10.1089/cap.2017.0085
  28. Yektaş Ç, Tufan AE, Sarıgedik E. Sleep habits of children diagnosed with attention/ deficit/ hyperactivity disorder and effects of treatment on sleep related parameters. Asian J Psychiatr. 2020;52:102045. https://doi.org/10.1016/j.ajp.2020.102045
  29. Sangal RB, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep. 2006;29(12):1573-1585. https://doi.org/10.1093/sleep/29.12.1573
  30. Niemczyk J, Equit M, Hoffmann L, von Gontard A. Incontinence in children with treated attention-deficit/hyperactivity disorder. J Pediatr Urol. 2015;11(3):141.e1-6. https://doi.org/10.1016/j.jpurol.2015.02.009
  31. Eliezer DD, Lam C, Smith A, et al. Optimising the management of children with concomitant bladder dysfunction and behavioural disorders. Eur Child Adolesc Psychiatry. 2023;32(10):1989-1999. https://doi.org/10.1007/s00787-022-02016-4
  32. Adisu MA, Habtie TE, Munie MA, et al. Global prevalence of nocturnal enuresis and associated factors among children and adolescents: a systematic review and meta-analysis. Child Adolesc Psychiatry Ment Health. 2025;19(1):23. https://doi.org/10.1186/s13034-025-00880-x
  33. Shatkin JP. Atomoxetine for the treatment of pediatric nocturnal enuresis. J Child Adolesc Psychopharmacol. 2004;14(3):443-447. https://doi.org/10.1089/cap.2004.14.443
  34. Sumner CR, Schuh KJ, Sutton VK, et al. Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. J Child Adolesc Psychopharmacol. 2006;16(6):699-711. https://doi.org/10.1089/cap.2006.16.699
  35. Glazener CM, Evans JH. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev. 2002;(3):CD002112. https://doi.org/10.1002/14651858
  36. Ohtomo Y. Atomoxetine ameliorates nocturnal enuresis with subclinical attention-deficit/hyperactivity disorder. Pediatr Int. 2017;59(2):181-184. https://doi.org/10.1111/ped.13111
  37. Hergüner S, Hergüner A. Atomoxetine for encopresis in 2 children with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2012;32(2):302-303. https://doi.org/10.1097/JCP.0b013e3182499aba
  38. Türkoğlu S, Bilgiç A, Uzun N. Effectiveness of Atomoxetine in the Treatment of Children With Encopresis. J Clin Psychopharmacol. 2015;35(5):622-623. https://doi.org/10.1097/JCP.0000000000000369
  39. Yucel A, Yucel N, Oral E. The role of atomoxetine and sympathetic pathways in encopresis with ADHD. Bulletin of Clinical Psychopharmacology. 2015;25(1):93-94. https://doi.org/10.5455/bcp.20150104114115
  40. Roessner V, Eichele H, Stern JS, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry. 2022;31(3):425-441. https://doi.org/10.1007/s00787-021-01899-z
  41. Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65(12):1941-1949. https://doi.org/10.1212/01.wnl.0000188869.58300.a7
  42. Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord. 2008;11(4):470-481. https://doi.org/10.1177/1087054707306109
  43. Redmond SM, Ash AC, Li H, Zhang Y. Links Among Attention-Deficit/Hyperactivity Disorder Symptoms and Psycholinguistic Abilities Are Different for Children With and Without Developmental Language Disorder. Am J Speech Lang Pathol. 2024;33(5):2344-2363. https://doi.org/10.1044/2024_AJSLP-23-00388
  44. Druker K, Hennessey N, Mazzucchelli T, Beilby J. Elevated attention deficit hyperactivity disorder symptoms in children who stutter. J Fluency Disord. 2019;59:80-90. https://doi.org/10.1016/j.jfludis.2018.11.002
  45. Ahmadabadi F, Motamedi A, Zahed G, et al. Efficacy of Addition of Atomoxetine to Speech Therapy in Stuttering Severity of Children Aged 4—12 Years: A Double-Blind Randomized Controlled Trial. Iran J Child Neurol. 2022;16(3):47-56. https://doi.org/10.22037/ijcn.v16i3.34450
  46. Shaywitz BA, Williams DW, Fox BK, Wietecha LA. Reading outcomes of children and adolescents with attention-deficit/hyperactivity disorder and dyslexia following atomoxetine treatment. J Child Adolesc Psychopharmacol. 2014;24(8):419-425. https://doi.org/10.1089/cap.2013.0148
  47. Shaywitz S, Shaywitz B, Wietecha L, et al. Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial. J Child Adolesc Psychopharmacol. 2017;27(1):19-28. https://doi.org/10.1089/cap.2015.0189
  48. Wietecha L, Williams D, Shaywitz S, et al. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial. J Child Adolesc Psychopharmacol. 2013;23(9):605-613. https://doi.org/10.1089/cap.2013.0054
  49. Hongyao HE, Chun JI, Xiaoyan G, et al. Associative gene networks reveal novel candidates important for ADHD and dyslexia comorbidity. BMC Med Genomics. 2023;16(1):208. https://doi.org/10.1186/s12920-023-01502-1
  50. McBurnett K, Clemow D, Williams D, et al. Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms. J Child Adolesc Psychopharmacol. 2017;27(1):38-42. https://doi.org/10.1089/cap.2016.0115
  51. Burns GL, Becker SP. Sluggish Cognitive Tempo and ADHD Symptoms in a Nationally Representative Sample of US. Children: Differentiation Using Categorical and Dimensional Approaches. J Clin Child Adolesc Psychol. 2021;50(2):267-280. https://doi.org/10.1080/15374416.2019.1678165
  52. Yektas C, Tufan AE, Kaplan Karakaya ES, et al. Does the coexistence of attention deficit hyperactivity disorder and sluggish cognitive tempo affect the treatment response in children? Turkish J Clin Psych. 2023;26(3):177-185. https://doi.org/10.5505/kpd.2023.23500
  53. Чутко Л.С., Яковенко Е.А., Сурушкина С.Ю. и др. Клинико-нейрофизиологические проявления низкого когнитивного темпа у детей. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(5):120-127. https://doi.org/10.17116/jnevro2024124051120
  54. Tahıllıoğlu A, Ercan ES. Atomoxetine might be more effective in improving sluggish cognitive tempo symptoms after switching from methylphenidate: A case report. Clin Case Rep. 2020;9(2):612-617. https://doi.org/10.1002/ccr3.3592
  55. Brown TE, Chen J, Robertson B. Improved Executive Function in Adults Diagnosed With Attention-Deficit/ Hyperactivity Disorder as Measured by the Brown Attention-Deficit Disorder Scale Following Treatment With SHP465 Mixed Amphetamine Salts Extended-Release: Post Hoc Analyses From 2 Randomized, Placebo-Controlled Studies. J Atten Disord. 2022;26(2):256-266. https://doi.org/10.1177/1087054720961819
  56. Ramos-Galarza C, Brito D, Rodríguez B, et al. Systematic Review of Executive Function Stimulation Methods in the ADHD Population. J Clin Med. 2024;13(14):4208. https://doi.org/10.3390/jcm13144208
  57. Griffiths KR, Leikauf JE, Tsang TW, et al. Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: The ACTION randomized controlled trial. J Psychiatr Res. 2018;102:57-64. https://doi.org/10.1016/j.jpsychires.2018.03.009
  58. Taş Torun Y, Işik Taner Y, Güney E, İseri E. Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) versus atomoxetine on executive function improvement and clinical effectiveness in ADHD: A randomized controlled trial. Appl Neuropsychol Child. 2022;11(4):567-578. https://doi.org/10.1080/21622965.2020.1796667
  59. Adler L, Tanaka Y, Williams D, et al. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study. J Clin Psychopharmacol. 2014;34(4):461-466. https://doi.org/10.1097/JCP.0000000000000138
  60. Adler LA, Solanto M, Escobar R, et al. Executive Functioning Outcomes Over 6 Months of Atomoxetine for Adults With ADHD: Relationship to Maintenance of Response and Relapse Over the Subsequent 6 Months After Treatment. J Atten Disord. 2020;24(3):363-372. https://doi.org/10.1177/1087054716664411
  61. Bédard AC, Stein MA, Halperin JM, et al. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder. J Child Psychol Psychiatry. 2015;56(1):40-48. https://doi.org/10.1111/jcpp.12272
  62. Ince Tasdelen B, Karakaya E, Oztop DB. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2015;25(6):494-500. https://doi.org/10.1089/cap.2014.0155
  63. Wu CS, Shang CY, Lin HY, Gau SS. Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2021;31(3):187-196. https://doi.org/10.1089/cap.2020.0146
  64. Gioia GA, Isquith PK, Retzlaff PD, Espy KA. Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function (BRIEF) in a clinical sample. Child Neuropsychology. 2002;8(4):249-257. https://doi.org/10.1076/chin.8.4.249.13513
  65. Kohn MR, Tsang TW, Clarke SD. Efficacy and safety of atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorder. Clin Med Insights Pediatr. 2012;6:95-162. https://doi.org/10.4137/CMPed.S7868
  66. Bangs ME, Wietecha LA, Wang S, et al. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adolesc Psychopharmacol. 2014;24(8):426-434. https://doi.org/10.1089/cap.2014.0005
  67. Pozzi M, Carnovale C, Mazhar F, et al. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. J Clin Psychopharmacol. 2019;39(4):386-392. https://doi.org/10.1097/JCP.0000000000001058
  68. Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019;106(1):94-102. https://doi.org/10.1002/cpt.1409
  69. Guo HL, Wu DD, Fu D, et al. Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together. Transl Psychiatry. 2024;14(1):151. https://doi.org/10.1038/s41398-024-02859-2
  70. Nijenhuis M, Soree B, Jama WOM, et al. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate. Eur J Hum Genet. 2023;31(12):1364-1370. https://doi.org/10.1038/s41431-022-01262-z
slide-cover
slide-cover
slide-cover
slide-cover
slide-cover

Рекомендуем статьи по данной теме:

Глаукома и возрастная макулярная дегенерация: проблемы и перспективы профилактики и лечения сочетанной патологии. Часть 1. Эпидемиология и патогенез.Вестник офтальмологии. 2026;142(4):112-119

Распространенность психических расстройств и субсиндромального психического дистресса у пациентов с хроническими дерматозами: поперечное эпидемиологическое исследование.Журнал неврологии и психиатрии им. С.С. Корсакова. 2026;126(7):107-114

Биологическая роль нейровоспаления в патогенезе психических расстройств при легочной гипертензии.Журнал неврологии и психиатрии им. С.С. Корсакова. 2026;126(7):7-14

Анализ структуры коморбидной патологии у работников предприятия тяжелой промышленности.Профилактическая медицина. 2026;29(7):59-67

Возможности применения селективного анксиолитика Афобазола в клинической практике.Журнал неврологии и психиатрии им. С.С. Корсакова. 2026;126(6):29-37

Нарушения сна и течение атопического дерматита у детей.Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2026;126(5-2):105-109

Цифровые технологии в диагностике и лечении нарушений сна при посттравматическом стрессовом расстройстве.Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2026;126(5-2):87-94

Расстройства сна и хроническая ишемия головного мозга.Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2026;126(5-2):42-47

Коморбидность у пациентов с обструктивным апноэ сна. Часть 1. Общие вопросы.Профилактическая медицина. 2025;28(11):94-99

Прогностические факторы прогрессирования и риска неблагоприятных исходов хронической обструктивной болезни легких.Респираторная медицина. 2025;1(2):71-78

Издательство «Медиа Сфера»
РекламаДоставка/ОплатаО насКонтактыОбучение для редакцийПолитика конфиденциальностиПолитика обработки персональных данныхПубличная оферта на реализацию издательской продукции
ЖурналыПодпискаАрхивКнигиПроекты
  • RuStore

© 1998-2026

  • Телефоны издательства:

  • +7 (495) 482-41-18
  • +7 (495) 482-43-29

  • Прямой телефон отдела подписки
    (только по вопросам заказов и доставки журналов)

  • +7 (800) 250-18-12

  • пн-пт с 10:00 до 18:00

  • Telegram
  • VK
info@mediasphera.ru

  • Почтовый адрес:

  • Издательство «Медиа Сфера»,
    а/я 54, Москва, Россия, 127238

  • RuStore

© 1998-2026